FM 140 vs FM100 Study in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if there is a difference in transplant
outcomes between two different doses of melphalan given in combination with fludarabine
followed by transfusion of a related or unrelated volunteer donor's peripheral blood or bone
marrow progenitor cells (allogeneic stem cell transplant) in patients with multiple myeloma.
This study will also look at whether treatment with a antibody called rituximab against a
specific type of lymphocyte (B cell) will reduce the risks of developing graft versus host
disease after transplant. The safety of these treatments will also be compared.